Literature DB >> 15879632

Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor.

Anish A Desai1, James E McGuigan, Peter Draganov.   

Abstract

Patients with the Zollinger-Ellison syndrome are characterized by islet-cell tumors, striking gastric acid hypersecretion, and peptic ulcer disease. They often experience severe abdominal pain, diarrhea, and gastrointestinal bleeding with potentially life-threatening consequences. It is a rare syndrome caused by non-beta cell islet-cell tumors (gastrinomas) located in or in proximity to the pancreas. These tumors freely secrete gastrin, a peptide hormone that serves as a powerful stimulant of gastric acid secretion. Exuberant secretion of gastrin from the gastrinomas produces severe gastric acid hypersecretion that often leads to impressive peptic ulcer disease and the constellation of symptoms listed above. We describe a patient presenting with clinical manifestations characteristic of the ZES with strikingly elevated gastric acid secretion,multiple ulcers in the first and second portions of the duodenum and diarrhea, but in absence of islet-cell tumor and/or hypergastrinemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879632     DOI: 10.1385/IJGC:35:2:157

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  18 in total

1.  Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas.

Authors:  R M ZOLLINGER; E H ELLISON
Journal:  Ann Surg       Date:  1955-10       Impact factor: 12.969

2.  Mechanism of gastric acid hypersecretion in patients with islet cell tumor without hypergastrinemia: studies in rats.

Authors:  Y Song; W Y Chey; T M Chang; K Y Lee
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

Review 3.  Localization of gastrinomas.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1996-04

Review 4.  Zollinger-Ellison syndrome.

Authors:  J I Isenberg; J H Walsh; M I Grossman
Journal:  Gastroenterology       Date:  1973-07       Impact factor: 22.682

5.  Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.

Authors:  David C Metz; Elaine Soffer; Chris E Forsmark; Byron Cryer; William Chey; Wieslaw Bochenek; Joseph R Pisegna
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

6.  Non-gastrin secretogogue in ulcerogenic tumors of the pancreas.

Authors:  W Y Chey; T M Chang; H J Park; K Y Lee; R Escoffery; Y F Chen; A N Shah; D Hamilton; C H You; R Manguy
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

7.  Basophilic leukemia and the hypersecretion of gastric acid and pepsin.

Authors:  W Anderson; C A Helman; B I Hirschowitz
Journal:  Gastroenterology       Date:  1988-07       Impact factor: 22.682

8.  Changing concepts in the presentation, diagnosis and management of the Zollinger-Ellison syndrome.

Authors:  A S Mee; S Ismail; P C Bornman; I N Marks
Journal:  Q J Med       Date:  1983

9.  Gastrointestinal dysfunction in systemic mastocytosis. A prospective study.

Authors:  J A Cherner; R T Jensen; A Dubois; T M O'Dorisio; J D Gardner; D D Metcalfe
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

10.  Localization and resection of gastrinomas in Zollinger-Ellison syndrome.

Authors:  S B Vogel; M M Wolfe; J E McGuigan; I F Hawkins; R J Howard; E R Woodward
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

View more
  1 in total

Review 1.  Gastric acid hypersecretory states: recent insights and advances.

Authors:  Nauramy Osefo; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2009-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.